Your browser doesn't support javascript.
loading
Cultivation and Genomics Prove Long-Term Colonization of Donor's Bifidobacteria in Recurrent Clostridioides difficile Patients Treated With Fecal Microbiota Transplantation.
Jouhten, Hanne; Ronkainen, Aki; Aakko, Juhani; Salminen, Seppo; Mattila, Eero; Arkkila, Perttu; Satokari, Reetta.
Afiliação
  • Jouhten H; Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Ronkainen A; Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Aakko J; Functional Foods Forum, Faculty of Medicine, University of Turku, Turku, Finland.
  • Salminen S; Functional Foods Forum, Faculty of Medicine, University of Turku, Turku, Finland.
  • Mattila E; Department of Infectious Diseases, Helsinki University Hospital, Helsinki, Finland.
  • Arkkila P; Department of Gastroenterology, Helsinki University Hospital, Helsinki, Finland.
  • Satokari R; Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Front Microbiol ; 11: 1663, 2020.
Article em En | MEDLINE | ID: mdl-32760391
ABSTRACT
Fecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridioides difficile infection (rCDI) and it's also considered for treating other indications. Metagenomic studies have indicated that commensal donor bacteria may colonize FMT recipients, but cultivation has not been employed to verify strain-level colonization. We combined molecular profiling of Bifidobacterium populations with cultivation, molecular typing, and whole genome sequencing (WGS) to isolate and identify strains that were transferred from donors to recipients. Several Bifidobacterium strains from two donors were recovered from 13 recipients during the 1-year follow-up period after FMT. The strain identities were confirmed by WGS and comparative genomics. Our results show that specific donor-derived bifidobacteria can colonize rCDI patients for at least 1 year, and thus FMT may have long-term consequences for the recipient's microbiota and health. Conceptually, we demonstrate that FMT trials combined with microbial profiling can be used as a platform for discovering and isolating commensal strains with proven colonization capacity for potential therapeutic use.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article